These results suggest that disrupting PD-L1 expression in PDAC cells while up-regulating ZG16 can enhance immune activation by modulating cytokines/chemokines involved while simultaneously down-regulating immunosuppressive cytokines as well as tumor angiogenic factors. Here, ZG16 is linked to neoplasm.